Entrada Therapeutics Statistics
Total Valuation
TRDA has a market cap or net worth of $241.94 million. The enterprise value is $67.48 million.
| Market Cap | 241.94M |
| Enterprise Value | 67.48M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TRDA has 36.06 million shares outstanding. The number of shares has increased by 1.93% in one year.
| Current Share Class | 36.06M |
| Shares Outstanding | 36.06M |
| Shares Change (YoY) | +1.93% |
| Shares Change (QoQ) | +0.92% |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 52.51% |
| Float | 20.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 51.78 |
| Forward PS | 7.45 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.89, with a Debt / Equity ratio of 0.21.
| Current Ratio | 10.89 |
| Quick Ratio | 10.52 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.09% and return on invested capital (ROIC) is -280.08%.
| Return on Equity (ROE) | -54.09% |
| Return on Assets (ROA) | -29.20% |
| Return on Invested Capital (ROIC) | -280.08% |
| Return on Capital Employed (ROCE) | -62.93% |
| Weighted Average Cost of Capital (WACC) | 2.39% |
| Revenue Per Employee | $30,829 |
| Profits Per Employee | -$1.09M |
| Employee Count | 152 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TRDA has paid $819,000 in taxes.
| Income Tax | 819,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.19% in the last 52 weeks. The beta is -0.25, so TRDA's price volatility has been lower than the market average.
| Beta (5Y) | -0.25 |
| 52-Week Price Change | +25.19% |
| 50-Day Moving Average | 6.95 |
| 200-Day Moving Average | 9.51 |
| Relative Strength Index (RSI) | 46.12 |
| Average Volume (20 Days) | 309,879 |
Short Selling Information
The latest short interest is 2.35 million, so 6.51% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short Previous Month | 2.37M |
| Short % of Shares Out | 6.51% |
| Short % of Float | 11.67% |
| Short Ratio (days to cover) | 7.70 |
Income Statement
In the last 12 months, TRDA had revenue of $4.69 million and -$165.78 million in losses. Loss per share was -$3.97.
| Revenue | 4.69M |
| Gross Profit | -134.36M |
| Operating Income | -174.63M |
| Pretax Income | -164.96M |
| Net Income | -165.78M |
| EBITDA | -170.86M |
| EBIT | -174.63M |
| Loss Per Share | -$3.97 |
Balance Sheet
The company has $223.01 million in cash and $48.54 million in debt, with a net cash position of $174.46 million or $4.84 per share.
| Cash & Cash Equivalents | 223.01M |
| Total Debt | 48.54M |
| Net Cash | 174.46M |
| Net Cash Per Share | $4.84 |
| Equity (Book Value) | 233.41M |
| Book Value Per Share | 6.47 |
| Working Capital | 211.33M |
Cash Flow
In the last 12 months, operating cash flow was -$134.67 million and capital expenditures $323,000, giving a free cash flow of -$134.35 million.
| Operating Cash Flow | -134.67M |
| Capital Expenditures | 323,000 |
| Depreciation & Amortization | 3.76M |
| Net Borrowing | n/a |
| Free Cash Flow | -134.35M |
| FCF Per Share | -$3.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,726.53% |
| Pretax Margin | -3,520.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.93% |
| Shareholder Yield | -1.93% |
| Earnings Yield | -68.32% |
| FCF Yield | -55.37% |
Analyst Forecast
The average price target for TRDA is $19.00, which is 183.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 183.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -6.30% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TRDA has an Altman Z-Score of 0.16 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.16 |
| Piotroski F-Score | 1 |